预约演示
更新于：2025-06-21
SAR-439459
更新于：2025-06-21
概要
基本信息
关联
4
项与 SAR-439459 相关的临床试验NCT05231668
A Phase 1b, Single Ascending Dose, Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Activity of SAR439459 in Adults With Osteogenesis Imperfecta
NCT04729725
Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab
NCT04643002
Phase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agents Compared to Isatuximab With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma (RRMM) - Master Protocol
100 项与 SAR-439459 相关的临床结果
登录后查看更多信息
100 项与 SAR-439459 相关的转化医学
登录后查看更多信息
100 项与 SAR-439459 相关的专利（医药）
登录后查看更多信息
2
项与 SAR-439459 相关的文献（医药）2024-06-01CTS-Clinical and Translational Science
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study
Article
作者: Abbadessa, Giovanni ; Demers, Brigitte ; Grob, Jean-Jacques ; Wang, Rui ; Baranda, Joaquina C ; Vieito, Maria ; Barve, Minal ; Bechter, Oliver ; Robbrecht, Debbie ; Schadendorf, Dirk ; Johnson, Melissa ; Doger, Bernard ; Chen, Xiaofei ; Hodi, F Stephen ; Santoro, Armando ; Cantalloube, Cathy ; de Miguel, Maria Jose ; Lee, Jooyun ; Sullivan, Ryan ; Pouzin, Clemence ; Amrate, Amele
Abstract:
SAR439459 (SAR'459), a “second‐generation” human anti‐transforming growth factor beta (TGFβ) monoclonal antibody, enhances the activity of immune checkpoint inhibitors. In this phase I/Ib study, we evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of SAR'459 ± cemiplimab (intravenous) in patients with advanced solid tumors. Increasing doses of SAR'459 were administered every 2 or 3 weeks (Q2W, Q3W) alone (Part 1A) or with 3 mg/kg cemiplimab Q2W or 350 mg Q3W (Part 1B). In Part 2A (dose expansion), melanoma patients were randomly (1:1) administered 22.5 or 7.5 mg/kg SAR'459. In Part 2B (dose expansion), 22.5 mg/kg SAR'459 and 350 mg cemiplimab Q3W were administered. The primary end points were maximum tolerated dose (MTD) or maximum administered dose (MAD; Part 1), preliminary antitumor activity (Part 2B), and optimal monotherapy dose (Part 2A). Twenty‐eight and 24 patients were treated in Parts 1A and 1B, respectively; MTD was not reached, MAD was 15 (Q2W) and 22.5 mg/kg (Q3W) alone and in combination, respectively. Fourteen and 95 patients, including 14 hepatocellular carcinoma (HCC) patients, were treated in Parts 2A and 2B, respectively. The population PK model yielded satisfactory goodness‐of‐fit plots and adequately described the observed data by a two‐compartment PK model with linear elimination. Objective responses were not observed in Parts 1 and 2A. In Part 2B, objective response rate was 8.4% and 7.1% across tumor types and the HCC cohort, respectively. The most frequent treatment‐emergent adverse effects were hemorrhagic events (43.5%), keratoacanthoma (6.8%), and skin neoplasms (6.2%). Fatal bleeding occurred in 21.4% HCC patients despite the implementation of mitigation measures. SAR'459 monotherapy and combination with cemiplimab appeared relatively safe and tolerable in limited number of patients in dose escalation. However, the study was discontinued due to the unclear efficacy of SAR'459 and bleeding risk, particularly in HCC patients.
2024-02-01Clinical and translational science
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Article
作者: Garralda, Elena ; Simonelli, Matteo ; Schadendorf, Dirk ; Demers, Brigitte ; Wang, Rui ; Butler, Marcus O ; Rodriguez-Vida, Alejo ; Abbadessa, Giovanni ; Pomponio, Robert ; Lee, Joon Sang ; Grob, Jean-Jacques ; Robbrecht, Debbie ; Pons-Tostivint, Elvire ; Borbath, Ivan ; Wang, Hong ; Romano, Patricia Martin ; Doger, Bernard ; Bechter, Oliver ; Di Nicola, Massimo ; Ryu, Min-Hee ; Curigliano, Giuseppe ; Cheng, Tina ; Amrate, Amele
Abstract:
SAR439459, a ‘second‐generation’ human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody, inhibits all TGFβ isoforms and improves the antitumor activity of anti‐programmed cell death protein‐1 therapeutics. This study reports the pharmacodynamics (PD) and biomarker results from phase I/Ib first‐in‐human study of SAR439459 ± cemiplimab in patients with advanced solid tumors (NCT03192345). In dose‐escalation phase (Part 1), SAR439459 was administered intravenously at increasing doses either every 2 weeks (Q2W) or every 3 weeks (Q3W) with cemiplimab IV at 3 mg/kg Q2W or 350 mg Q3W, respectively, in patients with advanced solid tumors. In dose‐expansion phase (Part 2), patients with melanoma received SAR439459 IV Q3W at preliminary recommended phase II dose (pRP2D) of 22.5/7.5 mg/kg or at 22.5 mg/kg with cemiplimab 350 mg IV Q3W. Tumor biopsy and peripheral blood samples were collected for exploratory biomarker analyses to assess target engagement and PD, and results were correlated with patients' clinical parameters. SAR439459 ± cemiplimab showed decreased plasma and tissue TGFβ, downregulation of TGFβ‐pathway activation signature, modulation of peripheral natural killer (NK) and T cell expansion, proliferation, and increased secretion of CXCL10. Conversion of tumor tissue samples from ‘immune‐excluded’ to ‘immune‐infiltrated’ phenotype in a representative patient with melanoma SAR439459 22.5 mg/kg with cemiplimab was observed. In paired tumor and plasma, active and total TGFβ1 was more consistently elevated followed by TGFβ2, whereas TGFβ3 was only measurable (lower limit of quantitation ≥2.68 pg/mg) in tumors. SAR439459 ± cemiplimab showed expected peripheral PD effects and TGFβ alteration. However, further studies are needed to identify biomarkers of response.
5
项与 SAR-439459 相关的新闻（医药）2024-07-29
2024-07-25
疫苗临床2期临床1期临床3期信使RNA
2023-11-01
100 项与 SAR-439459 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性多发性骨髓瘤 | 临床2期 | 美国 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 澳大利亚 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 法国 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 德国 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 希腊 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 以色列 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 意大利 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 挪威 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 葡萄牙 | 2021-01-25 | |
| 难治性多发性骨髓瘤 | 临床2期 | 波多黎各 | 2021-01-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | 晚期恶性实体瘤 PD-1 | 3 | 鏇蓋蓋憲獵簾範鑰積觸(鬱糧選築觸廠築觸鏇夢) = Two grade 3 treatment-related adverse events were reported: rash 選鹹築艱鏇襯繭製膚餘 (窪壓鑰鏇願醖蓋壓觸顧 ) 更多 | 不佳 | 2025-04-28 | ||
临床1期 | 109 | (Part 2A) | 鬱範選膚蓋鬱網襯構壓(鏇鑰餘鹽艱糧窪齋糧蓋) = 100% of pts had at least one treatment emergent adverse event (AE), 67% were G≥3, 34% related G≥3, 17% G5, and 4% related G5. 顧膚築餘鬱艱鬱鏇襯憲 (製觸憲鹹網鏇獵簾窪構 ) 更多 | 不佳 | 2022-06-02 | ||
(Part 2B) | |||||||
临床1期 | 晚期恶性实体瘤 mesenchymal CRC | CMS4 phenotype | - | 鏇製顧艱壓膚簾廠繭壓(觸蓋積簾衊糧簾製廠襯) = a trend of increased 壓艱壓鹹選構鹹鹹鑰構 (廠範鏇憲艱襯艱夢鑰壓 ) 更多 | - | 2021-11-10 | ||
临床1期 | 52 | 壓鬱窪鹽淵醖網糧憲鹽(淵醖顧網夢遞衊窪憲襯) = 淵淵網鏇構壓蓋齋遞鏇 夢鬱衊鏇蓋齋範艱衊襯 (願願範壓齋憲鹹觸簾餘 ) 更多 | 积极 | 2021-05-20 | |||
壓鬱窪鹽淵醖網糧憲鹽(淵醖顧網夢遞衊窪憲襯) = 餘製鑰顧齋衊簾壓選壓 夢鬱衊鏇蓋齋範艱衊襯 (願願範壓齋憲鹹觸簾餘 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用